MedTrace Logo

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)

NCT06190093 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-02-25

No results posted yet for this study

Summary

Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.

Conditions

  • Neovascular Age-related Macular Degeneration
  • Age-Related Macular Degeneration
  • Wet Macular Degeneration

Interventions

BIOLOGICAL

bevacizumab

1.25 mg, intravitreal injection

BIOLOGICAL

ranibizumab

0.5mg, intravitreal injection

Sponsors & Collaborators

  • Outlook Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-24
Primary Completion
2024-11-07
Completion
2024-12-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06190093 on ClinicalTrials.gov